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OBJECTIVES This study examined the relative merits of digoxin, carvedilol, and their combination for the
management of patients with atrial fibrillation (AF) and heart failure (HF).
BACKGROUND In patients with AF and HF, both digoxin and beta-blockers reduce the ventricular rate, and
both may improve symptoms, but only beta-blockers have been shown to improve prognosis.
If combined therapy is not superior to beta-blockers alone, treatment of patients with HF and
AF could be simplified by stopping digoxin.
METHODS We enrolled 47 patients (29 males; mean age 68 years) with persistent AF and HF (mean left
ventricular ejection fraction [LVEF] 24%) in a randomized, double-blinded, placebo-controlled
study. In the first phase of the study, digoxin was compared with the combination of digoxin and
carvedilol (four months). In the second phase, digoxin was withdrawn in a double-blinded manner
in the carvedilol-treated arm, thus allowing a comparison between digoxin and carvedilol (six
months). Investigations were undertaken at baseline and at the end of each phase.
RESULTS Compared with digoxin alone, combination therapy lowered the ventricular rate on 24-h
ambulatory electrocardiographic monitoring (p  0.0001) and during submaximal exercise (p 
0.05), whereas LVEF (p 0.05) and symptom score (p 0.05) improved. In phase 2, there was
no significant difference between digoxin alone and carvedilol alone in any variable. The mean
ventricular rate rose and LVEF fell when patients switched from combination therapy to
carvedilol alone. Six-minute walk distance was not significantly influenced by any therapy.
CONCLUSIONS The combination of carvedilol and digoxin appears generally superior to either carvedilol or
digoxin alone in the management of AF in patients with HF. (J Am Coll Cardiol 2003;42:
1944–51) © 2003 by the American College of Cardiology Foundation
Digoxin has been used for over two centuries for the
treatment of heart failure (HF) and/or atrial fibrillation
(AF) and is currently standard therapy for patients with
persistent AF and HF. However, there is evidence that
digoxin is inadequate for controlling the ventricular rate
during exercise or when sympathetic tone is increased (1).
Furthermore, digoxin does not improve survival of patients
with HF and sinus rhythm, and there is little reason to
suppose that there would be a prognostic benefit in patients
with AF, assuming that ventricular rate control can be
obtained by other means (2).
Beta-blockers have been shown to improve the prognosis
of patients with HF and left ventricular (LV) systolic
dysfunction, a substantial minority of whom had AF as their
baseline rhythm (3–5). In patients without HF, beta-
blockers improve ventricular rate control in AF when added
to digoxin or when used alone (1). Among patients with AF
and HF, only a few trials have specifically investigated the
utility of adding a beta-blocker to digoxin (6–8). These
trials suggest that beta-blockers reduce ventricular rate,
improve ventricular function, and are well tolerated. How-
ever, these mechanistic studies used agents with high intrinsic
sympathomimetic activity (6,8), which are now generally
thought to be contraindicated in HF and were conducted
before the advent of angiotensin-converting enzyme inhibitors.
Furthermore, beta-blockers were added to digoxin in these
studies; no comparison between beta-blockers alone versus
digoxin alone, or the combination, was made.
The aim of this randomized, double-blinded study was to
compare the effects of digoxin alone, carvedilol (a beta-
blocker) alone and their combination in patients with HF
and persistent AF.
METHODS
Patients. We recruited patients with persistent AF (1
month) and HF who were receiving digoxin and diuretics.
Heart failure was defined as appropriate symptoms of HF
for more than two months and echocardiographic evidence
of cardiac dysfunction (left ventricular ejection fraction
[LVEF] 40% or preserved LV systolic function, together
with LV hypertrophy, suggesting diastolic dysfunction in
the absence of an alternative potential cause of symptoms).
The following were exclusion criteria: heart rate (HR) at
rest 60 beats/min, systolic blood pressure (BP) 90 mm
Hg, sick sinus syndrome or complete heart block, current
treatment with a beta-blocker or HR-lowering calcium
channel antagonist or 200 mg amiodarone, recent major
cardiovascular event or procedure, asthma or reversible
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obstructive airways disease, serum creatinine 250 mol/l
or significant hepatic disease, uncorrected significant valvu-
lar heart disease, or any life-threatening noncardiac disease.
All patients gave written, informed consent, and the proto-
col was approved by the local Ethics Committee.
Study design. In a randomized, controlled, double-
blinded, parallel-arm study, the following treatments were
assessed: digoxin alone versus the combination of digoxin
and carvedilol (phase 1, duration four months) and digoxin
alone versus carvedilol alone (phase 2, duration six months)
(Fig. 1). Withdrawal of digoxin at the same time as
initiating and uptitrating beta-blockers could increase the
risk of worsening HF. Therefore, a complex study design
was adopted to allow double-blinded initiation of carvedilol
first, followed by double-blinded withdrawal of digoxin,
once maintenance doses of carvedilol had been achieved.
Investigations were performed at baseline and after each
phase. Before randomization, patients had their digoxin dose
increased, if necessary, to achieve optimal resting ventricular
rate control (defined as a ventricular rate of at least 90
beats/min on a 12-lead electrocardiogram [ECG]). Plasma
concentrations of digoxin were monitored to avoid toxicity,
except in the second phase, which would have compromised
the double-blinded nature of the study. The reference levels for
toxicity were 1.2 to 2.6 nmol/l. Forty-seven patients were
randomized into two groups: 24 into the carvedilol treated
group and 23 into the placebo group. In phase 1, both groups
continued open-label digoxin; in addition, one group received
double-blind carvedilol while the other received double-blind
placebo. The starting dose of carvedilol was 3.125 mg b.i.d.,
and this was increased at two-week intervals to the target dose
of 25 mg b.i.d. (uptitration period of two months) or, for
patients weighing more than 85 kg, 50 mg b.i.d. In phase 2,
open-label digoxin was replaced by double-blind placebo in the
group already receiving double-blind carvedilol. Open-label
digoxin was replaced with double-blind digoxin in the group
receiving double-blind placebo in phase 1. Patients were
reviewed two weeks after open-label digoxin was withdrawn or
substituted to monitor for worsening HF. Repeat investiga-
tions were carried out eight weeks after open-label digoxin
withdrawal or substitution (or six months after initial random-
ization). The randomization process involved a paired coding
system during the two phases, so that no patient was left
without some ventricular rate control therapy. This design
allowed a double-blinded comparison between digoxin alone
and carvedilol alone at the end of six-month follow-up.
Investigations. The primary prespecified outcomes for the
study were: 1) LVEF by ECG-gated radionuclide ventricu-
lography; 2) ventricular rate control by 24-h ambulatory ECG;
and 3) symptoms at the end of phase 2 of the study. We also
investigated exercise tolerance by 6-min corridor walk distance
in all patients. In a subset of 23 patients, ventricular rate control
Abbreviations and Acronyms
AF  atrial fibrillation
BNP  brain natriuretic peptide
BP  blood pressure
ECG  electrocardiogram/electrocardiographic
HF  heart failure
HR  heart rate
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RPP  rate-pressure product
Figure 1. Study design. *Randomization at this stage determined pairing of therapies in phase 2. Carv.  carvedilol; DB  double-blind; Dig.  digoxin;
OL  open-label.
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during steady-state bicycle exercise test was assessed. Plasma
concentrations of brain natriuretic peptide (BNP) (C-terminal,
Peninsula Labs, Belmont, California) were measured.
Primary end point measurements. ASSESSMENT OF LV
FUNCTION. For radionuclide ventriculography, 5 mg stan-
nous pyrophosphate was injected intravenously into the
patient 15 min before the injection of 500 MBq of
technetium-99m pertechnetate. A gamma camera equipped
with a general, all-purpose, parallel-hole collimator inter-
faced to a dedicated computer, linked to MAPS LINK
medical system, was used to analyze counts. The LVEF was
determined from the left anterior oblique projection using a
manual method of drawing the region of interest, together
with estimation of background correction. Mean LVEF was
calculated in standard fashion after background correction.
Calculated mean LVEF in this study was averaged from all
RR intervals (both long and short) during the 10 min of
recording in the left anterior oblique projection. A previous
study has demonstrated that ECG-gated time-activity
curves for LVEF for all beats are very similar to the averaged
single-beat data (9).
VENTRICULAR RATE CONTROL. The 24-h ambulatory
ECGs were obtained in all subjects during normal, unrestricted
out-of-hospital activity by using a miniature tape recorder with
a crystal time-generated reference track that allows correction
for recording and replay speed errors to within 0.5%. For a tape
to be eligible it had to have21 h of analyzable data with AF
as the basic rhythm. The ECG recordings were processed with
standard precision on the MEDILOG Excel 2 system (OX-
FORD Instruments, Abingdon, UK).
Assessment of symptoms. We used a self-administered,
quantitative questionnaire designed to measure the patient’s
perception of the frequency and severity of symptoms and
their functional capacity. A 4-point scale (0  absent; 3 
severe symptoms) was used for the following symptoms;
chest pain/discomfort, fatigue, shortness of breath, and
palpitations. For the first three symptoms, patients were
asked to grade severity at rest, during walking at normal
pace, and while climbing stairs. We also asked about the
patient’s “global” health or their sense of well-being. The
responses were summed to produce a symptom score rang-
ing from 0 (no symptoms) to 33 (worst symptoms).
Exercise tests. All patients underwent a standard 6-min
corridor walk test with verbal encouragement given to the
patient every 2 min. A subgroup of 11 patients in the
carvedilol-treated arm and 12 patients in the placebo arm
exercised on a bicycle against a resistance of 50 W at 40
rotations/min for 5 min. The remainder was either unable
to exercise due to co-morbidities (n  14), such as arthritis
or hemiparesis due to stroke, or declined (n  10). Blood
pressure was recorded manually by a sphygmomanometer at
rest (pre-exercise) and 3 and 5 min into exercise. The last
10 s of recorded ECG of each minute was used to determine
the ventricular rate for that minute. All patients exercised in
the morning between 9 AM and 12 PM.
Statistics. We used LVEF to determine the sample size.
Because there are no data directly comparing digoxin to
carvedilol for a change in LVEF in patients with HF, we
powered the study on the expected differences in ejection
fraction when comparing digoxin with the combination of
carvedilol and digoxin. The mean increase in LVEF in con-
trolled studies of carvedilol in HF patients is8% (10); a large
percentage of the population in these trials was on maintenance
digoxin therapy. Given a postulated standard deviation of 9.5%
for ejection fraction, the sample size was estimated to be 44
patients (22 in each limb; beta  0.80, alpha  0.05).
Absolute values between groups were not compared
because of expected heterogeneity in individual electro-
physiologic characteristics and consequently differing re-
sponses to pharmacologic intervention. Rather, for each
patient, the change from baseline for the results of investi-
gations was determined at the end of phase 1 (four months)
and phase 2 (six months). The change from baseline (i.e.,
before the first randomization) was then compared between
groups. A paired t test for intragroup comparisons and a
two-sided t test for intergroup comparisons were used for
normally distributed data. The Mann-Whitney U test was
used to compare differences for nonparametric data. For
paired sample non-normal data, the Wilcoxon signed rank
test was used. The Z test was used for the comparison of
proportions, as appropriate. A value of p  0.05 indicated
statistical significance. To estimate the time of peak ven-
tricular response (acrophase) and diurnal variation in the
hourly mean ventricular rate for treatments, the mean
hourly ventricular rate of each group was modeled by
cosinor analysis (11). Group data are presented as the mean
 SD for parametric data and the median value with
interquartile ranges for nonparametric data. Analysis was
undertaken by SPSS statistical software, version 9.
Our statistical analysis plan did not include analysis of
variance (ANOVA), as the principle analysis of interest was the
comparison between monotherapies, with combination ther-
apy being a necessary intermediate step of novel mechanistic
but not novel clinical significance (as far larger subsets of
patients with AF were included in landmark trials of beta-
blockers in HF). However, we also explored the results of
repeated measures ANOVA on the three normally distributed
variables (change from baseline): 24-h ambulatory mean HR,
systolic BP, and 6-min walk distance. The results for this
analysis did not differ from the predefined analysis plan.
RESULTS
Tables 1 and 2 describe the demographic and clinical
variables at baseline. The groups were generally well
matched. Most patients were treated with angiotensin-
converting enzyme inhibitors and warfarin in addition to
digoxin and diuretics. Although inclusion criteria did not
stipulate the presence of significant LV systolic dysfunction
and allowed inclusion of patients with convincing evidence
of HF with preserved LV systolic function, in fact, only
three of the 47 patients recruited to this study had LVEF
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40% (2 in the carvedilol-treated group and 1 in the
digoxin-treated only group). All but three patients were
titrated to a target dose of carvedilol (25 mg b.i.d.); two were
titrated to 12.5 mg b.i.d.; and one to 6.25 mg b.i.d. No
patient reverted to sinus rhythm during the trial.
Changes from baseline for 24-h mean HR, systolic BP,
and 6-min walk distance were normally distributed data,
whereas changes from baseline for LVEF, symptom score,
and BNP were not normally distributed and analyzed as
such.
Phase 1: digoxin alone versus carvedilol and digoxin in
combination. Twenty of 24 patients randomized to carve-
dilol and 21 of 23 patients randomized to placebo com-
pleted phase 1. The mean daily dose of carvedilol achieved
in the active arm was 47.6 mg. The plasma digoxin
concentration did not differ significantly between groups
either at baseline (Table 1) or at the end of phase 1 (1.2 
0.5 vs. 1.4  0.5 nmol/l for digoxin alone vs. combination,
respectively, p  0.2). However, two patients on carvedilol
developed possible symptoms of digoxin toxicity and had
their digoxin dose reduced, although serum concentrations
remained in the therapeutic range.
No significant change in any study variable occurred when
adding placebo to digoxin. Compared with placebo, the addi-
tion of carvedilol to digoxin reduced the mean 24-h ventricular
rate (p  0.0001) and improved symptoms scores (p  0.05)
and LVEF (p 0.05). New York Heart Association (NYHA)
functional class also tended to improve (p  0.08) with
combination treatment. Changes in BNP and 6-min walk
distances were not significant (Table 2).
Phase 2: digoxin alone versus carvedilol alone. In phase 2
of the study, double-blinded withdrawal of digoxin from
patients on carvedilol led, by intragroup comparison, to a
significant increase in the 24-h mean HR and a decline in
LVEF. When the intergroup changes from baseline for
these variables were compared, no significant difference
between digoxin alone and carvedilol alone was noted.
However, BNP values increased significantly more for
carvedilol alone than for digoxin alone. There was conflict-
ing evidence for symptomatic deterioration on withdrawal
of digoxin. Symptom scores of patients who remained on
therapy favored carvedilol (p  0.007). However, three
patients in the carvedilol-treated group developed worsen-
ing symptoms of HF, associated with a rise in HR, leading
to an exit from the study on days 11, 18, and 24 days after
withdrawal of digoxin. Preceding NYHA class, ventricular
function, or plasma BNP did not predict deterioration. One
patient developed worsening symptoms of HF when switch-
ing from open-label to double-blind digoxin. After assign-
ing maximum symptom scores to withdrawals, a significant
difference in symptoms between carvedilol alone and
digoxin alone was no longer noted (Table 2).
Ventricular rate control (Figs. 2 and 3). Figures 2A to
2C, illustrates the 24-h ventricular rate profile for each
phase of the study. Compared with digoxin alone, the
Table 1. Population Characteristics at Baseline
Carvedilol-Treated
Group (n  24)
Placebo Group
(n  23)
Age (yrs) 68.6  9.4 68.4  9.8 NS
Males 14 15 NS
IHD etiology 8 11 NS
Duration of AF (weeks) 152.8  204 109.2  123.4 NS
Previous cardioversion
attempts (n)
0.3  0.6 0.7  1.7 NS
Resting heart rate on ECG
(beats/min)
88.5  24.5 82.4  19.7 NS
LVEF (%) 23.7  10.4 24.7  9.5 NS
LVEDD (mm) 53.3  10.4 54.2  9.7 NS
LA size (mm) 48.9  8.3 47.9  8.0 NS
NYHA class NS
I 1 1
II 11 16
III 9 6
IV 3 0
Digoxin dose (mg) 0.25  0.11 0.24  0.1 NS
Digoxin plasma concentration
(nmol/l)
1.55  0.8 1.52  0.7 NS
ACE inhibitors 17 (71%) 16 (71%) NS
Anticoagulated 19 (79%) 19 (83%) NS
Data are presented as the mean value  SD or number (%) of subjects.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; ECG 
electrocardiogram; IHD  ischemic heart disease; LA  left atrial size; LVEDD 
left ventricular end-diastolic dimension; LVEF  left ventricular ejection fraction;
NS  not significant; NYHA  New York Heart Association.
Table 2. Intergroup Comparisons of Treatment Effect
Baseline Values
Phase 1 (4 Months) Phase 2 (6 Months)
Pre-Carvedilol
Group
Placebo
Group Combination Digoxin p Value* Carvedilol Digoxin p Value*
24-h mean heart rate
(beats/min)
81.8  11.7 75.9  12 65.2  15‡ 74.9  11.2  0.0001 88.8  18.7 75.7  10.6 0.13
Systolic BP (mm Hg) 128  19 132  23 121  24 134  20 0.11 112  16‡ 129  20 0.45
LVEF (%) 23.7  10.4 24.7  9.5 30.6  9.6‡ 26  12.4§ 0.048 21.6  11 27.2  11.7 0.15
Symptom score† 12 (7.25–17) 10 (4–17) 7 (3–12.5)‡ 8 (3–15) 0.039 6 (2–17)‡ 8 (5–15.5) 0.08
6-min WD (ms) 353  109 354  143 394  82 414  114 0.46 374  108 403  126 0.49
BNP (pg/ml) 86 (63–176.8) 122 (59–211) 153 (107–200) 120.5 (87–188) 0.11 183 (118–312)‡ 79.5 (57–155) 0.03
*The p value is a test of significance for the change from baseline between the respective groups. †In phase 2, patients withdrawn due to worsening heart failure were assigned
NYHA class IV and maximum symptom scores of 33 each. ‡Intragroup changes compared with baseline, p  0.05. §One patient in this group, phase 1, had a technically
inadequate radionuclide ventriculogram. Data are presented as the mean value  SD or median value (interquartile range).
BNP brain natriuretic peptide; BP blood pressure; Combination combination treatment with carvedilol and digoxin; LVEF left ventricular ejection fraction; WD
walk distance.
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addition of carvedilol lowered the mean 24-h ventricular
rate during both day and night (Fig. 2B). Carvedilol alone
and digoxin alone were equally effective in controlling the
daytime ventricular rate, but digoxin lowered the nocturnal
HR to a greater extent (Fig. 2C). Carvedilol significantly
reduced day-night differences in the mean hourly HR, in
combination with digoxin or alone, principally by at-
tenuating the increase in HR during waking hours (Figs. 2B
and 2C). The peak ventricular rate occurred at 15:00 h
for all treatment groups. The median maximum ventricular
rate was 176 beats/min on digoxin alone versus 134 beats/
min on combination treatment (phase 1; p  0.05). Carve-
dilol alone and digoxin alone appeared equally effective in
reducing the median maximal ventricular rate.
Figure 2. (A to C) Mean hourly heart rate (HR) as influenced by treatment regimen(s) during ambulatory 24-h electrocardiogram. Points with an asterisk
represent significant differences in HR between groups. At baseline, by chance, the ventricular rate tended to be higher in the carvedilol-treated group
throughout 24 h, but this difference was only statistically significant for a few hours. Analyses are intergroup changes from baseline values.
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Compared with digoxin, combination therapy reduced the
ventricular rate at rest and throughout steady-state exercise
(Fig. 3B) (peak ventricular rate 106 vs. 123 beats/min on
digoxin; p  0.05). Carvedilol alone and digoxin alone ap-
peared equally effective in controlling exercise HR (Fig. 3C).
The rate of rise in ventricular rate during exercise was similar
for carvedilol or digoxin alone and combination treatment.
The peak rate-pressure product (RPP) was reduced on
combination therapy compared with digoxin alone (15,003 
6,684 vs. 19,176  5,463; p  0.007). However, in phase 2,
comparing carvedilol and digoxin monotherapies, peak RPP
was not significantly different (13,583  3,213 vs. 17,017 
3,557, p 0.23). The peak ventricular rate was similar (114
21 vs. 116  18 beats/min, p  0.8), but systolic BP (127 
12 vs. 157  19 mm Hg, p  0.002) was lower for carvedilol
than digoxin.
Pauses. Compared with digoxin, combination therapy re-
sulted in a greater mean maximum pause (2.9  0.8 vs. 2.4
 0.6 s, p  0.05). The mean maximum pause was greater
for digoxin alone compared to carvedilol alone in phase 2
(2.3  0.7 s vs. 1.8  0.73 s for digoxin and carvedilol,
respectively; p  0.05). However, there was no significant
difference in the numbers of pauses 3 s, either during the
day (8 AM to 8 PM) or night (8 PM to 8 AM) for any treatment
group.
Adverse events. In phase 1, three patients withdrew be-
cause of adverse effects subsequent to the initiation of
carvedilol (one each with gastrointestinal disturbance, tired-
ness, and bronchospasm), and one withdrew in the placebo
group (self-withdrawal). Four patients, as noted earlier,
withdrew because of worsening HF during phase 2. There
were three deaths during the study: two in the group
Figure 3. Ventricular rate during submaximal exercise. (A) Pre-carvedilol (open triangles) and placebo (solid triangles) groups at baseline. (B) Phase 1
(four months): combination therapy (solid squares) versus digoxin alone (open squares). (C) Phase 2 (six months): digoxin alone (open circles) versus
carvedilol alone (solid circles).
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randomized to carvedilol (myocardial infarction in phase 1
and stroke in phase 2) and one in the group randomized to
placebo (postoperative sepsis after transurethral resection of
the prostate during phase 1).
DISCUSSION
Few studies have focused on the management of patients
with both AF and HF, conditions that often co-exist (12).
Our results demonstrate that, in patients with persistent AF
and HF, the combination of digoxin and carvedilol, com-
pared with digoxin alone, lowers the ventricular rate and
reduces symptoms. However, few differences between carve-
dilol and digoxin, used as single agents, were apparent. In
particular, no difference in the mean 24-h HR was observed.
Withdrawal of digoxin from patients with AF treated with
carvedilol appeared generally deleterious. This study, there-
fore, is the first to demonstrate the continued value of
digoxin for the treatment of persistent AF in the setting of
HF in the presence of a beta-blocker.
Ventricular rate control and LV function. A reduction in
the ventricular rate during exercise and 24-h ambulatory
ECG monitoring was less than that anticipated with carve-
dilol alone compared with digoxin alone (12). This suggests
that both increased vagal tone and reduced sympathetic
activation are important in controlling ventricular rate in
patients with HF and AF (Figs. 2B and 3B). The sympa-
tholytic effects of digoxin may also be complementary to
those of beta-blockade (13). Digoxin was more effective at
reducing the nocturnal HR, reflecting the importance of
parasympathetic activation when sympathetic tone is low.
Beta-blockers consistently reduce end-diastolic volume and
improve LVEF both in patients with chronic HF in sinus
rhythm (10) and in those with AF (5), but the mechanisms
underlying this effect are uncertain. An increase in LVEF with
the addition of carvedilol could reflect a nonspecific response to
a reduction in the ventricular rate. There is some evidence of
HR-dependent cardiomyopathy in patients with AF and
suboptimal ventricular rate control (12).
No previous study has investigated the utility of digoxin
in patients with HF and persistent AF treated with beta-
blockers. This is important given concerns about polyphar-
macy in patients with HF. For those who tolerated digoxin
withdrawal, the ejection fraction declined by a median of
9%, whereas the mean 24-h ventricular rate rose by 22
beats/min to a mean of 88 beats/min. The latter was
unexpected, as digoxin withdrawal has not been shown to
cause such a marked increase in HR or reduction in
ventricular function in patients in sinus rhythm (14). It
suggests that the atrioventricular node may be less suscep-
tible than the sinoatrial node to the effects of beta-blockers
in patients with HF. Alternatively, the withdrawal of
digoxin may reduce baroreflex receptor sensitivity, removing
the tonic inhibition of central sympathetic drive, thereby
limiting the effects of beta-blockade (13). Our findings,
therefore, do not support the notion that the introduction of
beta-blockers as standard treatment of HF obviates the need
for digoxin in the presence of AF.
A potential criticism of this study is the accuracy of the
assessment of LV function in patients with AF, due to the
large variation in the RR interval. However, Bacharach et al.
(9) showed that the average of single-beat values plotted
against preceding RR intervals were very similar to one
ECG-gated time-activity curve (as used in this study). Inagaki
et al. (15) also showed that ECG-gated radionuclide ventricu-
lography is reliable, reproducible, and sensitive to change in
patients with AF.
Symptoms. There were significant improvements in symp-
tom scores with the double-blinded addition of carvedilol to
digoxin (Table 2), as demonstrated in other studies of HF,
presumably reflecting the effects of therapy on underlying
ventricular function (3). Most patients did not deteriorate
symptomatically upon withdrawal of digoxin, despite a
decline in ventricular function. This could reflect a protec-
tive effect of increased BNP levels or some other action of
carvedilol, such as peripheral vasodilation. No patient with
severe HF deteriorated clinically after digoxin withdrawal.
All three patients who deteriorated symptomatically, neces-
sitating withdrawal from study, were in NYHA class I or II
at the end of phase 1. Longer follow-up on combination
therapy might have prevented deterioration on digoxin
withdrawal. However, longer follow-up on carvedilol
monotherapy might have allowed declining cardiac function
to be translated into a worse clinical outcome more often.
Natriuretic peptides. Plasma concentrations of BNP
tended to rise when carvedilol was added to digoxin, rose
further when digoxin was withdrawn, and did not predict
which patients would deteriorate upon withdrawal of digoxin.
Increases in natriuretic peptides have also been noted in studies
of beta-blockers in patients in sinus rhythm (16) and may
reflect increases in ventricular filling pressure, conversely this
could be part of their therapeutic action of beta-blockers (17).
These data suggest that natriuretic peptides may not be a useful
aid to the management of HF with beta-blockers.
Previous studies. Synergistic effects of digoxin and beta-
blockade in controlling the ventricular rate in AF have been
demonstrated in previous studies, although these small
studies had few patients with HF (1). It is uncertain
whether all beta-blockers would exert the same benefits in
patients with AF and HF, most of whom are currently treated
with digoxin. A post hoc analysis of Cardiac Insufficiency
BIsoprolol Study (CIBIS II) suggested that, in patients with
AF, bisoprolol had no impact on survival or hospitalization for
HF (18). However, retrospective analyses of the U.S. carvedilol
HF trials program suggested that the benefit of carvedilol was
similar in the presence or absence of AF (5), whereas a greater
benefit of carvedilol on death and hospitalization was reported
among patients taking digoxin, although only a minority had
AF (19). Recently, the Carvedilol Or Metoprolol European
Trial (COMET) has suggested that carvedilol exerts a greater
effect on mortality than metoprolol, but data on patients with
AF are not yet available (20).
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Potential pharmacologic alternatives to beta-blockers for
the control of ventricular rate in patients with AF and HF
include diltiazem and amiodarone. Concerns exist about the
safety of diltiazem in patients with HF (21). Deedwania et
al. (22), in a post hoc subgroup analysis of the Congestive
Heart Failure-Survival Trial of Anti-arrhythmic Therapy
(CHF-STAT) trial, demonstrated that the ventricular rate
was significantly reduced with amiodarone. Furthermore,
spontaneous cardioversion occurred in 31% of those on
amiodarone but only 8% of those on placebo at one year.
The risk of long-term side effects with amiodarone and the
known mortality benefits of beta-blockers render the latter
group of agents preferable for the control of ventricular rate
in patients with persistent AF and LV systolic dysfunction.
An alternative treatment strategy in this patient popula-
tion is repeated cardioversion and prophylactic anti-
arrhythmic therapy to maintain sinus rhythm. However, in
the presence of HF and long-established AF, the failure of
cardioversion, toxicity of anti-arrhythmic drugs, and early
relapse are major drawbacks (12). A number of trials have
investigated the utility of cardioversion versus a strategy of
rate control for atrial fibrillation (23–25). None has sug-
gested that cardioversion is superior in terms of improving
symptoms, reducing stroke, or improving survival. Ventric-
ular rate control with anticoagulation therefore seems an
appropriate strategy in this population until either a sub-
group is identified that would benefit from a policy of
repeated cardioversion or more effective and safer methods
of maintaining sinus rhythm are developed.
Conclusions. This study suggests that the combination of
digoxin and carvedilol reduces symptoms, improves ventric-
ular function, and leads to better ventricular rate control
than either agent alone and therefore should be considered
the standard treatment for HF patients with persistent AF.
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